Tokai University Hospital

Isehara-city, Kanagawa 2591193

2 studies enrolling now · 5 studies all time

What they study most

Anemia, Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Myelofibrosis, Myeloproliferative Disorders, Neoplasms, Post-Polycythemia Vera Myelofibrosis, Primary Myelofibrosis

Studies at this site

• Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation — Recruiting now
• Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells — Recruiting now
• An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions — Running, not enrolling
• A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma — Running, not enrolling
• A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia — Completed